extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
af067944f1
commit
f6e42527c1
5 changed files with 68 additions and 1 deletions
|
|
@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
|
|||
|
||||
At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Trump Administration's November 2025 Medicare GLP-1 deal achieved $245/month pricing (82% below list) with narrow eligibility criteria targeting only high-risk patients with comorbidities. This fundamentally changes the cost-effectiveness calculus: under capitation, plans bearing full risk see drug costs offset by downstream savings in the specific population where multi-organ protection creates highest per-patient value. The narrow eligibility (~10% of Medicare beneficiaries) limits system-level inflationary impact while potentially making the therapy cost-effective for MA plans. This challenges the 'inflationary through 2035' conclusion by demonstrating that targeted coverage with deep price concessions can change the economics.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
|
|||
|
||||
No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The $50/month out-of-pocket maximum for tirzepatide starting April 2026 removes most financial barriers for eligible Medicare beneficiaries. Combined with the narrow eligibility criteria targeting high-risk patients with comorbidities (who have stronger clinical motivation to persist), this may improve adherence rates beyond the 15% two-year persistence seen in non-diabetic obesity patients. The deal structure specifically targets the population where both clinical benefit and persistence are likely to be highest.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
|
|||
|
||||
The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
|
||||
|
||||
The Trump Administration's Medicare GLP-1 deal sets a $50/month out-of-pocket maximum for tirzepatide starting April 2026, directly addressing the affordability barrier. This pricing structure (down from typical Medicare Part D cost-sharing) confirms that affordability is a modifiable driver of persistence, not an immutable patient characteristic. The deal's focus on removing financial barriers for Medicare beneficiaries validates the hypothesis that discontinuation rates are driven by cost, not just clinical factors.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-cms-rulemaking-as-novel-drug-pricing-mechanism.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16",
|
||||
"manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-cms-rulemaking-as-novel-drug-pricing-mechanism.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor",
|
||||
"manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-cms-rulemaking-as-novel-drug-pricing-mechanism.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-11-06
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: news
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -45,3 +49,16 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
|
||||
EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare/Medicaid price for semaglutide and tirzepatide: $245/month
|
||||
- General price through TrumpRx: $350/month (down from ~$1,350/month injectable)
|
||||
- Oral Wegovy: $149-$299/month (launched January 2026)
|
||||
- Medicare beneficiaries: $50/month out-of-pocket maximum for tirzepatide starting April 2026
|
||||
- Future oral GLP-1s: initial dose priced at $150/month on TrumpRx
|
||||
- Medicare GLP-1 payment demonstration: July 2026
|
||||
- BALANCE Model in Medicaid: May 2026
|
||||
- BALANCE Model in Medicare Part D: January 2027
|
||||
- Eligibility: BMI ≥27 with prediabetes or cardiovascular disease history, or BMI >30 with heart failure, uncontrolled hypertension, or chronic kidney disease
|
||||
- ~10% of Medicare beneficiaries expected to be eligible
|
||||
|
|
|
|||
Loading…
Reference in a new issue